Results 201 to 210 of about 52,166 (258)

Exercise Modalities to Preserve Muscle Mass and Bone Health After Metabolic Bariatric Surgery. [PDF]

J Cachexia Sarcopenia Muscle
Goldenshluger A, Friedman L, Turjeman T, Yavetz R, Raziel A, Goitein D, Markus I, Kais H, Sternfeld R, Trachtenberg E, Dubnov-Raz G, Mhaler I, Youngster I, Peled D, Amedi R, Keidar A, Livingston EH, Sakran N, Dicker D, Gepner Y.   +19 more
europepmc   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Analysis of the trajectory of depressive symptoms and influencing factors in patients undergoing metabolic and bariatric surgery. [PDF]

Front Endocrinol (Lausanne)
Zhang JL, Zhu Y, Shao Y, Wang J, Pu CY, Yang XY, Xu YJ, Shen Y.   +7 more
europepmc   +1 more source

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 762-773, September 2026.
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat, Haribhau Kangne, Rasmus Jansson‐Löfmark, Jens K. Hertel, Amin Rostami‐Hodjegan, Ida Robertsen, Aleksandra Galetin   +6 more
wiley   +1 more source

Exploring patients' perceptions and anticipated concerns regarding bariatric surgery. [PDF]

BMC Surg
Chen X, Cai CZ, Yang N, Zhou L, Yang H, Hua H, Song Y, Alias H, Huang Z, Wong LP, Lin Y.   +10 more
europepmc   +1 more source

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi, Mohammad Irshad, Jumana Alkandri, Anant Mashankar, Stuart R. Gray, Carel W. le Roux   +5 more
wiley   +1 more source

Anesthetic Management in Metabolic and Bariatric Surgery Among Anesthesiologists: Survey-Based Study in Poland. [PDF]

J Clin Med
Dobruchowska-Kęsikowska E, Wityk M, Dowgiałło-Gornowicz N.   +2 more
europepmc   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed   +8 more
wiley   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bariatric surgery

The Lancet Diabetes & Endocrinology, 2014
Essential facts: Type 2 diabetes is linked closely to obesity. Bariatric surgery can lead to dramatic improvements in the management of the condition, according to the National Institute for Health and Care Excellence (NICE). There are two main types of bariatric surgery.
Adam, Safwaan, Syed, Akheel
  +13 more sources